Is SRT2104 legal in the United Kingdom?

The sirtuin-activating drug that actually reached randomised human trials, built to succeed where resveratrol's potency failed. Its human results were modest and it did not advance.

Sirtuins were the biggest idea in longevity biology in the 2000s, and resveratrol was supposed to be the drug. When resveratrol turned out to be too weak and too poorly absorbed, the response was to build purpose-designed sirtuin-activating compounds that were orders of magnitude more potent.

Mechanism: Designed as a sirtuin-activating compound targeting SIRT1, an NAD-dependent protein deacetylase. SIRT1 deacetylates targets including PGC-1alpha, FOXO transcription factors and p53, and it was proposed as a mediator of dietary restriction benefits.

Regulatory history: Never approved. The programme did not advance to a marketed product.

Licenses medicines for the UK market. A compound without a marketing authorisation is an unlicensed medicine, which can only lawfully be supplied for human use through a prescriber under the specials scheme, not sold as a research product.

The classification above is the The Longevity Archive reading of Medicines and Healthcare products Regulatory Agency listings for SRT2104 at the reviewed date, not a legal opinion. Rules change, and importing, prescribing and possessing a compound can each be treated differently. Check the regulator directly before acting on anything here.